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Abstract
Background: Adequate bowel preparation is an essential prerequisite for complete mucosal visualization during
colonoscopy. Polyethylene glycol (PEG) solutions are commonly used. However the large volume of the solution is
often poorly tolerated. Addition of Lubiprostone (LB) could improve the adequacy of standard PEG preparation &
reduce requirement. The aims to assess adequacy of PEG preparation with addition of single dose LB (24mcg) vs
placebo and efficacy of reduced dose PEG + LB compared with full dose PEG + LB.
Methods: Single center prospective double blind randomized controlled trial. Part I: 442 patients for colonoscopy
randomized to receive placebo (GrA) or single dose of LB (GrB) prior to PEG preparation. Quality of bowel
preparation graded 0–9 according to Boston Bowel Preparation Scale (BBPS). BBPS-9: excellent and BBPS 0–4: repeat
procedure.
Part II: 146 patients randomized to receive LB + 1.5 L PEG (GrC; 75) or LB + 1 L PEG (GrD; 71). BBPS score compared
with GrB (2 L PEG).
Results: Part I: 442 patients (221 GrA & 221 Gr B). LB resulted in significant improvement in total BBPS (7.44 + 0.14
vs. 6.36 + 0.16, p < 0.0001). 66.5 % Gr B vs 38 % Gr A had excellent prep; 42.5 % GrB vs 24 % GrA had adequate
prep. Repeat procedure needed 9.5 % Gr B vs 16.7 % Gr A (P < 0.01).
Part II: No difference in BBPS scores with lower doses (Gr C&D) compared to standard (GrB) (Mean BBPS 7.44 + 0.14
GrA,7.30 + 0.25 GrC;7.25 + 0.26 GrD;p >0.05).
Conclusion: Single dose LB prior to PEG significantly enhanced bowel preparation compared to PEG alone. There
was no significant difference in quality of preparation with lower doses of PEG when combined with LB.
Trial registration: The study protocol was approved by institutional review board and the trial was registered on
March 22, 2011 with clinicaltrials.gov (NCT01324284).
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Background
Colonoscopy is the current standard method for exam-
ination of the colon. Bowel cleansing prior to colonos-
copy is the essential prerequisite to ensure complete
mucosal visualization and lesion identification [1, 2].
Suboptimal preparations are associated with missed
diagnoses, longer procedure times and increased costs
related to the repeat procedures and shortened intervals
between procedures [3–5]. In fact, poor bowel prepar-
ation and incomplete evaluation have accounted for a
larger share of cancer risk than polyp characteristics for
all defined population subgroups [6, 7]. Inadequate prep-
arations have been noted in around 25 % cases in the US
[4, 8]. This has been attributed primarily to poor patient
tolerance to the standard colon preparations.
Osmotically balanced polyethylene glycol (PEG)- elec-
trolyte bowel lavage solutions were introduced in 1980 [9].
These PEG based solutions are the most commonly used
bowel preparations today [9]. They have high efficacy, are
safe and are associated with minimal fluid and electrolyte
imbalance. However the major drawback of these prepara-
tions is the taste and the large volumes required with as-
sociated nausea, cramping and vomiting [10]. This often
results in poor compliance and tolerance with resultant
poor preparation & improper visualization. The compli-
ance rates for colonoscopy screening has been reported to
be as low as 34 % in adults greater than 50 year of age [5].
A pooled analysis of 15 trials found that at least 29 % of
patients were unable to complete their PEG solution [11].
Lubiprostone (LB) is a locally acting selective Type 2
chloride channel activator which causes intestinal fluid
secretion. This results in increased softened stool and in-
creased intestinal transit without the loss of either net
intravascular fluid or electrolytes [12]. Peak plasma
levels occur approximately 1.14 h after oral administra-
tion of a single 24 microgram dose, and the half-life of
lubiprostone (t½) has been estimated at approximately
3 h [13, 14]. LB is currently approved for the treatment
of chronic idiopathic constipation and is generally well
tolerated with an excellent side effect profile. Even long
term usage has not shown clinically significant changes
in electrolyte levels [12, 15].
Our hypothesis was that administration of LB prior
to bowel preparation would improve the adequacy of
standard PEG preparation. Additionally it could re-
duce the dosage requirement of PEG and improve
patient tolerability. Accordingly we conducted this
prospective double blinded randomized placebo con-
trolled trial. The primary objective was to evaluate
the efficacy of standard PEG preparation with the
addition of single dose LB (24mcg) compared to a
placebo preparation. Subsequently we assessed the
adequacy of reduced [1 l and 1.5 l (L)] doses of PEG
preparation on addition of LB pretreatment.
Methods
This was a single center prospective double blind ran-
domized controlled trial to compare quality of bowel
preparation using PEG vs. PEG with LB. After observa-
tion of significant improvement in bowel preparation
with addition of LB, we undertook second part of this
study where we evaluated if addition of LB facilitated
dose reduction of PEG. The study protocol was ap-
proved by institutional review board and the trial was
registered with clinicaltrials.gov (NCT01324284). Re-
cruitment, enrollment, randomization, withdrawal and
completion were done according to the consort guide-
lines (Fig. 1).
Participants
We prospectively offered enrollment to patients between
ages of 18 and 75 years referred for outpatient colonos-
copy to Asian Institute of Gastroenterology, Hyderabad
from March to July 2011. Exclusion criteria included ac-
tive GI bleeding, renal insufficiency (creatinine ≥ 1.6), de-
mentia, recent myocardial infarction (in past 8 weeks),
symptomatic heart failure (NYHA class C or D), gastro-
paresis, gastric outlet obstruction, ileus, toxic megaco-
lon, suspected colonic obstruction, pregnancy and
lactation. Informed consent was taken from the patients
prior to enrolment.
Randomization
All subjects attended an informational session before
colonoscopy where they were counseled about the na-
ture of study and an informed written consent was ob-
tained. The Participants were randomized in two groups
for the Part 1 study. The research coordinator used
computer generated block randomization to allocate the
patients in standard of care 2 L PEG group (Group A)
or 2 L PEG with LB group(Group B) [16]. The patients
in group A were given a placebo pill identical in size,
shape and color to LB pill. In the second part of the
study, the Participants were randomly assigned to 1.5 L
PEG + LB (Group C) and 1 L PEG + LB (Group D). All
patients, endoscopists and endoscopy nursing and sup-
port staff were blinded to patient allocation. All patients
were given appropriate oral and written instructions re-
garding the lavage solution, tablets and diet.
Bowel Preparation
Part 1
On the day of procedure, group B was given one 24 mcg
tablet of LB (Sun Pharmaceutical Industries Ltd.). Group
A was given a placebo identical in appearance to LB tab-
let which was also supplied by Sun pharmaceuticals Ltd.
One hour after LB or placebo ingestion, the patients
were given 2 L PEG solution with electrolytes (polyethyl-
ene glycol 118 g, sod. chloride 2.93 gm, potassium
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chloride 1.484 gm, sod bicarbonate 3.37 gm, anhydrous
sodium sulfate 11.36 g) (Peglec, Tablets India Ltd). They
were instructed to take 200 cc every 10 min till the en-
tire solution was consumed. The subjects received stan-
dardized diet instructions which did not require any
overnight fasting or special diet the day prior to the col-
onoscopy. They were instructed to take clear liquid diet
while taking colonoscopy preparation followed by nil per
oral (NPO) status till the end of procedure.
Part 2
After completion of Part 1 and analysis of results, two
additional groups were added to investigate if decreasing
PEG dose affects colonoscopy preparation. In the Part 2,
all patients in group C and group D received 24 mcg of
LB. Patients in group C were given 1.5 L of PEG solution
while group D were given 1 L PEG one hour after taking
LB. Standardized diet and colonoscopy lavage instruc-
tions were unchanged between Part 1 and Part 2.
Colonoscopy
All colonoscopies were performed by 4 experienced gas-
troenterologists (minimum experience of 1000 proce-
dures) at the Asian Institute of Gastroenterology. A
standard protocol for insertion, withdrawal and observa-
tion was followed. All colonoscopies were performed
using video colonoscopes (CF 145, Olympus, Japan)
under moderate propofol sedation. The colon segment
including rectum and extending up to the splenic flexure
was termed as descending colon; the segment between
splenic flexure and hepatic flexure was termed trans-
verse colon; while colon segment proximal to hepatic
flexure, including the cecum was termed right colon for
the purpose of this study. A complete colonoscopy was
defined as reaching the caecum determined by the
visualization and documentation of the ileocaecal valve
and appendicular orifice.
During the insertion of the scope, two representative
pictures were taken from each of these three segments
to document the colon prep. All colonoscopies were
done the same day of preparation. An early colonoscopy
was defined as a procedure initiated before 4 pm while
those started after 4 pm were considered late procedure.
Colon cleansing scale
We used Boston bowel prep scale (BBPS) score to evalu-
ate the adequacy of the preparation [17, 18]. Each co-
lonic segment was graded from 0 to 3 based on quality
of the prep. Aggregate score was obtained by adding the
score for all 3 segments, thus resulting in a score be-
tween 0 and 9. A score ≤ 4 was considered a poor prep,
resulting in recommendation for a repeat procedure.
However, the patients were evaluated only on the scores
for the first procedure and the repeat procedure was not
scored for the purpose of the study. A score of 8–9 was
considered excellent prep while a score of 5–7 was
Fig. 1 Consort flow diagram
Banerjee et al. BMC Gastroenterology  (2016) 16:133 Page 3 of 9
considered adequate prep. The colon prep was graded
by analyzing photo documentation obtained during a
colonoscopy by four gastroenterologists (RB, MT, HC,
SA and NS) randomized to the study groups.
Inter-observer agreement
All endoscopists Participating in the study were given a
half an hour presentation on Boston bowel prep scores
and on photo documentation of prep. A calibration exer-
cise was performed for the gastroenterologists involved
in scoring the prep.
Statistical analysis
In Part 1, colonoscopy prep scores between 2 L PEG
without or with Lubiprostone (Group A and B) were
evaluated. A sample size of at least 200 subjects was re-
quired to give an 80 % power at a 2 sided α of 0.05 to
detect a 3 point difference in the BBPS score. In Part 2,
the efficacy of bowel prep regimens containing lubipros-
tone with varying volumes of PEG namely 2, 1.5 and 1 L
(Group B, C and D) were evaluated. A Chi-square test
was used for nominal data while student’s t-test or
ANOVA was used for continuous data. For non-
parametric data, Man-Whitney U-test (for 2 groups) or
Kruskal-Wallis test (for 3 groups) were used. A 2 tailed
p value < 0.05 was considered significant. All study mem-




A total of 600 subjects were screened. 56 patients did
not meet the inclusion criteria, 84 declined to Partici-
pate. 2 subjects did not come back for procedure.
Initially 458 patients were enrolled in the study of
which 228 patients were allocated to group A and 230
patients were allocated to group B. 16 patients (7 from
group A and 9 from Group B) in whom colonoscopy
could not be completed were excluded from the analysis.
The indications for colonoscopy were primarily chronic
lower abdominal pain and bloody diarrhoea. There was
no significant difference in indications for colonoscopy
between the two groups (Table 1) . The average age was
45.8 years, average body weight 62.6 Kg and 71 % pa-
tients were male. The baseline characteristics of age,
gender, height, weight, comorbid illness including dia-
betes and dietary habits were similar in both the groups
(Table 2).
Addition of lubiprostone resulted in significant im-
provement in total BBPS score (7.44 ± 0.14 vs. 6.36 ±
0.16, Mean ± SE, p < 0.0001) (Fig. 2). 66.5 % patient in
group B and 38 % patients in group A had excellent
prep, 24 % in group A and 42.5 % in group B had ad-
equate prep while 9.5 % patients in group B and 16.7 %
patients in Group A had poor prep (P < 0.01) (Fig. 3).
Overall 90.5 % patients in group B and 83.3 % patients
in group A had excellent or adequate prep (P < 0.01).
Lubiprostone improved BBP scores in all three segments
of colon including the right colon (Fig. 4).
Part II
Given the significant improvement in bowel prep quality
with addition of lubiprostone, we undertook the second
Part of the study where we added two arms with re-
duced doses of PEG; 1.5 L PEG with LB (Group C) and
1 L PEG with LB(Group D). The investigators were
blinded to the allocation.
A total of 75 patients enrolled in group C and 71 pa-
tients in group D were enrolled in to the second part. As
the inclusion, exclusion criteria and methods were simi-
lar we also included Group B (lubiprostone with 2 L
PEG) in this comparison. At baseline age, gender and
dietary habits were similar in all three groups. Group D
had less college graduates compared to group B and C.
Significantly less number of patients had diabetes and







Constipation 16.6 %(37) 15 %(33)
Chronic lower abdominal pain 31 %(69) 34 %(75)
Diarrhea 8.8 %(19) 10 %(22)
Blood in motions 21 %(46) 17.5 %(39)
Unexplained weight loss 1.9 %(4) 1 %(2)
Anemia under evaluation 2.7 %(6) 2.5 %(6)
IBD follow up 14 %(31) 16 %(36)
Family H/O CRC or polyposis 1.2 %(3) 0.8 %(2)
Evaluation of abnormality by other imaging 2 %(4) 1.8 %(4)
Others 0.8 % (2) 1 %(2)
Table 2 Baseline characteristics of subjects





Age, Mean (SD) 45.8 (14.7) 45.9 (15.2)
Male, n (%) 154 (69.7 %) 160 (72.4 %)
Height in cm, Mean (SD) 160.9 (9.0) 161.4 (10.1)
Weight, Kg, Mean (SD) 63.3 (13.7) 61.9 (14.3)
College graduate, n (%) 95 (42.9 %) 122 (55.2 %)
Vegetarian Diet, n (%) 31 (27.6 %) 70 (31.6 %)
Rice based diet, n (%) 190 (86 %) 193 (83.7 %)
Prior colonoscopy, n (%) 60 (27.6 %) 52 (23.5 %)
Co-morbid illness, n (%) 94 (42.5 %) 79 (35.7 %)
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comorbid illness in group B compared to the other two
groups.
No difference was seen in the over-all colonoscopy
prep scores across the three groups. Mean BBPS scores
were 7.44 ± 0.14, 7.30 ± 0.25 and 7.25 ± 0.26 in group B,C
and D respectively (p > 0.05) (Fig. 5). There was no dif-
ference in patients with poor prep requiring repeat pro-
cedures across the three groups (9.5, 12, and 11.7 % in
group B, C and D respectively, p > 0.05) (Fig. 6). There
was a non-significant trend towards excellent prep with
higher PEG dose (66, 60 and 54.9 % in group B, C and
D). The decrease in proportion of patients with excellent
prep in lower PEG dose was replaced by higher propor-
tion of patients with adequate prep in those groups (24,
28 and 33.8 % in group B, C and D respectively).
Discussion
It is widely accepted that the quality of bowel prepar-
ation has a direct bearing on the diagnostic accuracy
and therapeutic safety of colonoscopy [4, 19, 20]. Recent
studies have shown an adenoma miss rate of 33 to 46 %
in those with inadequate bowel preparation at the time
of their screening colonoscopy [19, 20] and is considered
Fig. 2 Mean BBPS score with and without Lubiprostone prior to PEG preparation
Fig. 3 Quality of preparation with the addition of Lubiprostone (BBS score 8-9: excellent; 5–7: adequate; <4: poor prep/repeat)
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to be one of the major factors associated with post col-
onoscopy colorectal cancer [8].
This study addresses three important issues relevant to
bowel preparation: a) the quality of preparation b) the
reduced PEG dosage needed for adequate preparation &
c) effective same day preparation. We have assessed the
adequacy of LB pretreatment to standard PEG prepar-
ation for colonoscopy. The addition of LB produced a
significantly better colon cleansing throughout the colon
including the right colon. The number of repeat proce-
dures was also significantly lower compared to that of
the PEG only group. This demonstrates that LB could be
an important adjunct to standard bowel preparation to
allow a consistent & reliable colonoscopy.
Previous clinical studies have shown a success rate for
bowel cleansing with PEG based preparations ranging
from 56 to 76 % [21, 22]. In our study it was 90.3 % with
addition of LB. This suggests that LB provided an add-
itional laxative effect resulting in the significantly better
preparation. The accelerated small intestinal and colonic
transit time with LB with increased bowel movement
frequency could have contributed to the efficacy.
Fig. 4 Improved BBPS scores in all three segments of colon including the right colon with addition of Lubiprostone
Fig. 5 Mean BBPS scores with 2, 1.5 and 1 L volume of PEG on addition of Lubiprostone
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The large volume of PEG based formulations with re-
sultant distension, nausea and vomiting is currently the
largest barrier for patient acceptance & compliance. Low
volume PEG formulations represent an important alterna-
tive to standard volume preparations to reduce the dis-
comfort and inconvenience of bowel preparations [23, 24].
Studies have shown comparable results for low volume
PEG formulations with respect to ease of consumption,
acceptability, or the endoscopists’ satisfaction with the
quality of bowel preparation [25–29]. A low volume PEG
preparation with ascorbic acid has been shown to be an
effective alternative to the standard 4 L PEG [30]. How-
ever prokinetics like cisapride did not improve bowel
cleansing though the nausea and vomiting was reduced
[31]. Results with the addition of Tegaserod, a 5HT recep-
tor agonist was also discouraging with no change in toler-
ance, effectiveness or adverse effects [32]. A combination
therapy with Bisacodyl (same cost as LB) is available but
the safety profile has been doubted [33, 34]. In fact the ini-
tial combination therapy with 20 mg Bisacodyl has been
reduced to 5 mg due to adverse side effects including the
risk of ischaemic colitis [34, 35].
Strengel et al. have earlier used LB as a pretreatment for
split dose colonoscopy preparation in 200 patients for
CRC screening with improved cleansing quality [36]. Split
dosing has been recommended to improve patient toler-
ance [37–41]. However Ell C et al. in a meta-analysis have
demonstrated that even single dosing intake was effective
in more than 70 % of patients. The timing of the intake
could therefore be decided based on the patient’s conveni-
ence [42]. Our findings appear similar. Additionally, our
study is noteworthy since we included all symptomatic pa-
tients referred for diagnostic colonoscopy and was not
limited to colorectal cancer screening. No dietary restric-
tions were advocated. A single time preparation of 2- L
alone was given and majority of procedures were done on
the same day. Cleanliness in the right colon was less satis-
factory with low volume 2 L PEG than with 4 L PEG in a
few studies [43, 44]. However in our study there was bet-
ter cleansing of the right colon as well.
Same-day bowel cleansing for colonoscopy has been
practiced in parts of Asia for many years. Endoscopists
in the western world are now enthusiastically evaluating
this approach evidenced by an increased number of
reports describing same-day preparation. A number of
studies have shown the benefit of taking the whole prep-
aration in the morning of a scheduled afternoon colon-
oscopy. Matro R et al. have shown that the overall
efficacy was same between morning only and split dos-
ing of bowel preparation [45]. Gurudu SR et al. retro-
spectively reviewed the colonoscopy records of 1345
subjects who underwent afternoon colonoscopy. They
concluded that a same-day PEG bowel preparation yields
significantly improved colonic preparation for afternoon
colonoscopy compared with preparations completed the
evening prior to examination [46]. In fact the US Multi-
Society Task Force on Colorectal Cancer has recently
recommended same-day regimen as an acceptable
Fig. 6 Quality of preparation (BBP score) with 2, 1.5 & 1 L PEG preparations. Note: No significant difference in poor preparations/repeat
procedures with lower doses
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alternative to split dosing, especially for patients under-
going an afternoon examination [47].
Our study is the first study to demonstrate that even
reduced doses of PEG & same day preparation can pro-
duce adequate bowel cleansing with the addition of LB.
This use of a more practical single day low volume PEG
regimen could definitely improve patient compliance to
CRC screening guidelines in the future. In fact, same day
preparation has recently been recommended as a useful
tip for a better colonoscopy [48, 49].
This study does have some limitations. It is a single
center study where only outpatients were recruited. The
relatively mobile patients with detailed explanation of
the bowel preparation methods prior to the procedure
could have improved compliance and the results. It was
not an outcome study and as such the lesion miss rate
was not evaluated. We are unable to comment whether
improved bowel cleansing is associated with an in-
creased adenoma detection rate. However BPSS scores
have been shown to correlate with polyp detection rate
in earlier studies [17].
Colonoscopy is now the accepted standard for large
bowel evaluation. Screening colonoscopies with removal/
sampling of adenomatous polyps have reduced the inci-
dence and mortality from colorectal cancer. However the
hassles of a large volume bowel preparation, the preproce-
dure dietary restrictions have significantly impacted patient
compliance and tolerability. Our study highlights that pre-
treatment with a single dose of Lubiprostone can improve
bowel cleansing with significantly reduced rate of repeat
procedures. Even reduced doses of PEG could be used with
no impact on overall quality of preparation. This study is a
step forward towards easy same day colonoscopy. Further
validation studies in different population cohorts are re-
quired before incorporation into standard colon prepar-
ation guidelines.
Conclusion
Single dose LB prior to PEG significantly enhanced
bowel preparation compared to PEG alone. There was
no significant difference in quality of preparation with
lower doses of PEG when combined with LB.
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